Oral Bisphosphonate Risk Slight, But Dental Patients Should Be Aware, ADA Says(Inapoi)
People taking oral bisphosphonates, a type of drug used to treat osteoporosis, osteopenia and Paget's disease of bone, should be aware of potential risks when undergoing certain dental procedures, according to guidelines published in this month's Journal of the American Dental Association (ADA).
Relying on a small but growing number of reports linking bisphosphonate drugs
to incidences of osteonecrosis of the jaw (dead bone tissue), a panel of experts
convened by the ADA believes dental patients who are taking oral bisphosphonate
drugs should discuss the risks they face when undergoing procedures that involve
the jaw bone, such as tooth extraction or placing implants, with their dentist.
Dentists and their patients should carefully consider these procedures, as well
as alternative dental therapies. Patients may also want to discuss this information
in the context of their overall health and treatment options with their physician.
The ADA recommends that a comprehensive oral evaluation be carried out on all
patients about to begin therapy with oral bisphosphonates (or as soon as possible
after beginning therapy), and that patients on these drugs be educated on maintaining
oral hygiene, which is the best way to prevent oral diseases that may require
dental surgery.
The ADA notes that dentists, generally, will not need to modify dental treatments
based solely on oral bisphosphonate therapy. Further, patients should understand
that the risk for developing osteonecrosis of the jaw is considered very small
and that the vast majority of patients taking an oral bisphosphonate do not
develop any oral complication.
Sursa: American Dental Association
Data: 15.08.2006
Link: http://www.dentalcompare.com/news.asp?newsid=146120
Introdus de: admin
:: recomanda unui prieten
|
